-
公开(公告)号:US20060004066A1
公开(公告)日:2006-01-05
申请号:US10983981
申请日:2004-11-08
申请人: Elisabeth Morris , Sonya Glasson , Jason Xiang
发明人: Elisabeth Morris , Sonya Glasson , Jason Xiang
IPC分类号: A61K31/429 , A61K31/424 , A61K31/4188
CPC分类号: C07D213/30 , A61K31/4188 , A61K31/424 , A61K31/429 , C07C311/29 , C07C311/46 , C07C2601/08 , C07C2602/10 , C07D213/64 , C07D213/643 , C07D215/14 , C07D215/227 , C07D215/233 , C07D217/18 , C07D235/12 , C07D239/34 , C07D239/60 , C07D261/14 , C07D263/22 , C07D263/58 , C07D277/64 , C07D277/68 , C07D295/096 , C07D295/192 , C07D307/79 , C07D307/80 , C07D307/82 , C07D307/84 , C07D319/18 , C07D321/10 , C07D333/20 , C07D333/36 , C07D333/66
摘要: The present invention relates to methods of treating ADAMTS-5-associated diseases and particularly osteoarthritis comprising administering an agent capable of modulating ADMATS-5 activity to a subject afflicted with the disease. The agent is preferably a biaryl sulfonamide compound. The invention is based, in part, on the discovery that transgenic animals that do not express functional ADAMTS-5 show a reduction in the degree of osteoarthritis after the induction of osteoarthritis as compared to WT animals. Furthermore, the ADAMTS-5 transgenic animals have reduced aggrecanase activity in articular tissue as compared to WT animals. These animals are good models for ADAMTS-5-associated diseases, and for screening of drugs useful in the treatment and/or prevention of these diseases. There are no other animal models in which the deletion of the activity of a single gene is capable of abrogating the course of osteoarthritis. Accordingly, these animals also show that osteoarthritis can be prevented and/or treated by administering to a subject an ADAMTS-5 inhibitory agent and particularly an agent capable of inhibiting the aggrecanase activity of ADAMTS-5.
摘要翻译: 本发明涉及治疗ADAMTS-5相关疾病,特别是骨关节炎的方法,其包括将能够将ADMATS-5活性调节至患有该疾病的受试者的药剂。 该试剂优选为联芳基磺酰胺化合物。 本发明部分地基于以下发现:与WT动物相比,不表达功能性ADAMTS-5的转基因动物在诱导骨关节炎之后表现出降低骨关节炎的程度。 此外,ADAMTS-5转基因动物与WT动物相比降低了关节组织中的聚集蛋白聚糖蛋白聚糖酶活性。 这些动物是ADAMTS-5相关疾病的良好模型,并且用于筛选可用于治疗和/或预防这些疾病的药物。 没有其他动物模型,其中单个基因的活性的缺失能够消除骨关节炎的过程。 因此,这些动物还显示可以通过向受试者施用ADAMTS-5抑制剂,特别是能够抑制ADAMTS-5的聚集蛋白聚糖酶活性的试剂来预防和/或治疗骨关节炎。
-
公开(公告)号:US20080311113A1
公开(公告)日:2008-12-18
申请号:US12123990
申请日:2008-05-20
IPC分类号: A61K39/395 , G01N33/566 , G01N33/53 , A61P3/00 , A61P1/00 , A61P9/00 , A61P25/00 , A61P21/00 , A61P35/04
CPC分类号: C07D213/30 , A61K31/4188 , A61K31/424 , A61K31/429 , C07C311/29 , C07C311/46 , C07C2601/08 , C07C2602/10 , C07D213/64 , C07D213/643 , C07D215/14 , C07D215/227 , C07D215/233 , C07D217/18 , C07D235/12 , C07D239/34 , C07D239/60 , C07D261/14 , C07D263/22 , C07D263/58 , C07D277/64 , C07D277/68 , C07D295/096 , C07D295/192 , C07D307/79 , C07D307/80 , C07D307/82 , C07D307/84 , C07D319/18 , C07D321/10 , C07D333/20 , C07D333/36 , C07D333/66
摘要: The present invention relates to methods of treating ADAMTS-5-associated diseases and particularly osteoarthritis comprising administering an agent capable of modulating ADMATS-5 activity to a subject afflicted with the disease. The agent is preferably a biaryl sulfonamide compound. The invention is based, in part, on the discovery that transgenic animals that do not express functional ADAMTS-5 show a reduction in the degree of osteoarthritis after the induction of osteoarthritis as compared to WT animals. Furthermore, the ADAMTS-5 transgenic animals have reduced aggrecanase activity in articular tissue as compared to WT animals. These animals are good models for ADAMTS-5-associated diseases, and for screening of drugs useful in the treatment and/or prevention of these diseases. There are no other animal models in which the deletion of the activity of a single gene is capable of abrogating the course of osteoarthritis. Accordingly, these animals also show that osteoarthritis can be prevented and/or treated by administering to a subject an ADAMTS-5 inhibitory agent and particularly an agent capable of inhibiting the aggrecanase activity of ADAMTS-5.
摘要翻译: 本发明涉及治疗ADAMTS-5相关疾病,特别是骨关节炎的方法,其包括将能够将ADMATS-5活性调节至患有该疾病的受试者的药剂。 该试剂优选为联芳基磺酰胺化合物。 本发明部分地基于以下发现:与WT动物相比,不表达功能性ADAMTS-5的转基因动物在诱导骨关节炎之后表现出降低骨关节炎的程度。 此外,ADAMTS-5转基因动物与WT动物相比降低了关节组织中的聚集蛋白聚糖蛋白聚糖酶活性。 这些动物是ADAMTS-5相关疾病的良好模型,并且用于筛选可用于治疗和/或预防这些疾病的药物。 没有其他动物模型,其中单个基因的活性的缺失能够消除骨关节炎的过程。 因此,这些动物还显示可以通过向受试者施用ADAMTS-5抑制剂,特别是能够抑制ADAMTS-5的聚集蛋白聚糖酶活性的试剂来预防和/或治疗骨关节炎。
-
公开(公告)号:US07390833B2
公开(公告)日:2008-06-24
申请号:US10983981
申请日:2004-11-08
IPC分类号: A01N41/02 , A01N37/34 , A01N37/30 , A01N37/12 , A01N37/44 , A61K31/275 , A61K31/205 , A61K31/195 , A61K31/255
CPC分类号: C07D213/30 , A61K31/4188 , A61K31/424 , A61K31/429 , C07C311/29 , C07C311/46 , C07C2601/08 , C07C2602/10 , C07D213/64 , C07D213/643 , C07D215/14 , C07D215/227 , C07D215/233 , C07D217/18 , C07D235/12 , C07D239/34 , C07D239/60 , C07D261/14 , C07D263/22 , C07D263/58 , C07D277/64 , C07D277/68 , C07D295/096 , C07D295/192 , C07D307/79 , C07D307/80 , C07D307/82 , C07D307/84 , C07D319/18 , C07D321/10 , C07D333/20 , C07D333/36 , C07D333/66
摘要: The present invention relates to methods of treating ADAMTS-5-associated diseases and particularly osteoarthritis comprising administering an agent capable of modulating ADMATS-5 activity to a subject afflicted with the disease. The agent is preferably a biaryl sulfonamide compound. The invention is based, in part, on the discovery that transgenic animals that do not express functional ADAMTS-5 show a reduction in the degree of osteoarthritis after the induction of osteoarthritis as compared to WT animals. Furthermore, the ADAMTS-5 transgenic animals have reduced aggrecanase activity in articular tissue as compared to WT animals. These animals are good models for ADAMTS-5-associated diseases, and for screening of drugs useful in the treatment and/or prevention of these diseases. There are no other animal models in which the deletion of the activity of a single gene is capable of abrogating the course of osteoarthritis. Accordingly, these animals also show that osteoarthritis can be prevented and/or treated by administering to a subject an ADAMTS-5 inhibitory agent and particularly an agent capable of inhibiting the aggrecanase activity of ADAMTS-5.
摘要翻译: 本发明涉及治疗ADAMTS-5相关疾病,特别是骨关节炎的方法,其包括将能够将ADMATS-5活性调节至患有该疾病的受试者的药剂。 该试剂优选为联芳基磺酰胺化合物。 本发明部分地基于以下发现:与WT动物相比,不表达功能性ADAMTS-5的转基因动物在诱导骨关节炎之后表现出降低骨关节炎的程度。 此外,ADAMTS-5转基因动物与WT动物相比降低了关节组织中的聚集蛋白聚糖蛋白聚糖酶活性。 这些动物是ADAMTS-5相关疾病的良好模型,并且用于筛选可用于治疗和/或预防这些疾病的药物。 没有其他动物模型,其中单个基因的活性的缺失能够消除骨关节炎的过程。 因此,这些动物还显示可以通过向受试者施用ADAMTS-5抑制剂,特别是能够抑制ADAMTS-5的聚集蛋白聚糖酶活性的试剂来预防和/或治疗骨关节炎。
-
-